ObjectiveTo explore the Influence of Insulin Determir combined with Repaglinide therapy on serum uric (UA)acid of newly diagnosed type 2 diabetic patients.MethodsA total of 36 newly diagnosed type 2 diabetic patients with HbA1c≥8.5% received Insulin Determir combined with Repaglinide therapy for 12 weeks in our hospital from Janurary to June 2016 were selected.A comparison on UA,fasting plasma glucose(FPG),2 h postprandial glucose(2 h PG), HbA1c,blood lipid,body weight,fasting insulin(FINS),homa-insulin resistance(Homa-IR)and insulin sensitivity index(ISI) were performed before and after the treatment.ResultsCompared with before treatment,ISI was significantly increased from(7.02±3.48)to(7.83±3.39)(P<0.05),UA,FPG,2 h PG,HbA1c,TG,LDL-C and Homa-IR were significantly decreased after the treatment(P<0.05),and while body weight and FINS had no statistically significant difference before and after the treatment(P>0.05).ConclusionInsulin Determir combined with Repaglinide therapy can effectively improve the insulin resistance and decrease level of serum UA in the newly diagnosed type 2 diabetic patients.